A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Clinical trial NCT06585488 · TERMINATED

Trial details

NCT number

NCT06585488

Sponsor

BeOne Medicines

Status

TERMINATED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2024-12-13

Primary completion

2026-04-23

Enrollment

47

View on ClinicalTrials.gov